StreetInsider.com News Articles

Form 8-K BIOGEN INC. For: Mar 11

Wed, 11 Mar 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260311/26147317.html

Form 8-K BIOGEN INC. For: Mar 11

Wed, 11 Mar 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260311/26147317.html

Oppenheimer Reiterates Outperform Rating on Biogen (BIIB): "continue to view SMA as an important franchise"

Wed, 11 Mar 2026 16:54:15 -0400

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $250.00 price target on Biogen (NASDAQ: BIIB)

The analyst commented, "BIIB reported additional Ph1b data of salanersen at MDA and shared Ph3 development plans, building on promising results presented at Cure SMA last year. We spoke to the BIIB team for details on this update. Overall, the new data continue to demonstrate a differentiated profile of salanersen, with clear and consistent efficacy seen in patients who received Zolgensma but had suboptimal clinical response. While the first pivotal study of salanersen, STELLAR-1, recently started enrolling, BIIB shared plans for additional programs to cover

Biogen reports positive salanersen trial results in SMA patients

Wed, 11 Mar 2026 08:00:44 -0400

Biogen Inc. (NASDAQ: BIIB) reported additional Phase 1b clinical trial results for salanersen, an experimental treatment for spinal muscular atrophy, at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference.

The study evaluated salanersen in 24 children aged 0.5-12 years who had received suboptimal results from prior gene therapy treatment. All participants received at least two doses of the drug at either 40 mg or 80 mg concentrations administered once yearly.

According to the company's statement, all 24 participants showed improvement on one or more clinical endpoints. Twelve participants achieved at least one new World Health Organization motor milestone, while all maintained

Biogen reports positive salanersen trial results in SMA patients

Wed, 11 Mar 2026 08:00:44 -0400

Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

Wed, 11 Mar 2026 08:00:00 -0400

New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapy
Salanersen is a novel antisense oligonucleotide and has the potential to deliver high efficacy in SMA with once-yearly dosing
Biogen also debuted the design of the Phase 3 salanersen clinical trial program which is being initiated at sites around the world

CAMBRIDGE, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) presented additional results from the Phase

Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

Wed, 11 Mar 2026 08:00:00 -0400

New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapy
Salanersen is a novel antisense oligonucleotide and has the potential to deliver high efficacy in SMA with once-yearly dosing
Biogen also debuted the design of the Phase 3 salanersen clinical trial program which is being initiated at sites around the world

CAMBRIDGE, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) presented additional results from the Phase

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

Thu, 05 Mar 2026 07:30:00 -0400

Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)
New Phase 1b data further illustrate potential of salanersen in SMA, as Phase 3 studies begin to evaluate this investigational drug that has the potential for high potency with once-yearly dosing

CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – will present new data and updates from its spinal muscle atrophy (SMA) research programs, including high dose nusinersen and salanersen, at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

Thu, 05 Mar 2026 07:30:00 -0400

Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)
New Phase 1b data further illustrate potential of salanersen in SMA, as Phase 3 studies begin to evaluate this investigational drug that has the potential for high potency with once-yearly dosing

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

Thu, 05 Mar 2026 07:30:00 -0400

Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)
New Phase 1b data further illustrate potential of salanersen in SMA, as Phase 3 studies begin to evaluate this investigational drug that has the potential for high potency with once-yearly dosing

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

Thu, 05 Mar 2026 07:30:00 -0400

Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)
New Phase 1b data further illustrate potential of salanersen in SMA, as Phase 3 studies begin to evaluate this investigational drug that has the potential for high potency with once-yearly dosing

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

Wed, 04 Mar 2026 17:05:00 -0400

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease–

–Data support ongoing global Phase 3 EMPEROR study–

BEDFORD, Mass. and CAMBRIDGE, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB), today announced the publication of data from studies of the investigational medicine zorevunersen in The New

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

Wed, 04 Mar 2026 17:05:00 -0400

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease–

–Data support ongoing global Phase 3 EMPEROR study–

BEDFORD, Mass. and CAMBRIDGE, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB), today announced the publication of data from studies of the investigational medicine zorevunersen in The New

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

Wed, 04 Mar 2026 17:05:00 -0400

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease–

–Data support ongoing global Phase 3 EMPEROR study–

BEDFORD, Mass. and CAMBRIDGE, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB), today announced the publication of data from studies of the investigational medicine zorevunersen in The New

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

Wed, 04 Mar 2026 17:05:00 -0400

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease–

–Data support ongoing global Phase 3 EMPEROR study–

BEDFORD, Mass. and CAMBRIDGE, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB), today announced the publication of data from studies of the investigational medicine zorevunersen in The New

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

Wed, 04 Mar 2026 17:05:00 -0400

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease–

–Data support ongoing global Phase 3 EMPEROR study–

BEDFORD, Mass. and CAMBRIDGE, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB), today announced the publication of data from studies of the investigational medicine zorevunersen in The New

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

Wed, 04 Mar 2026 17:05:00 -0400

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease–

–Data support ongoing global Phase 3 EMPEROR study–

BEDFORD, Mass. and CAMBRIDGE, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB), today announced the publication of data from studies of the investigational medicine zorevunersen in The New

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Tue, 24 Feb 2026 16:01:00 -0400

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 2:30 p.m. ET.
A live audio webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke’s website

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Tue, 24 Feb 2026 16:01:00 -0400

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 2:30 p.m. ET.
A live audio webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke’s website

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Tue, 24 Feb 2026 16:01:00 -0400

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 2:30 p.m. ET.
A live audio webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke’s website

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Tue, 24 Feb 2026 16:01:00 -0400

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 2:30 p.m. ET.
A live audio webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke’s website

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Tue, 24 Feb 2026 16:01:00 -0400

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 2:30 p.m. ET.
A live audio webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke’s website

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Tue, 24 Feb 2026 16:01:00 -0400

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 2:30 p.m. ET.
A live audio webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke’s website

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Tue, 24 Feb 2026 16:01:00 -0400

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 2:30 p.m. ET.
A live audio webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke’s website

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Tue, 24 Feb 2026 16:01:00 -0400

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 2:30 p.m. ET.
A live audio webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke’s website